• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrence

byBrittany Hasty, MDandDaniel Fisher
May 11, 2018
in Chronic Disease, Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls.

2. There was no difference in all-cause mortality between the two treatment groups.

Evidence Rating: 1 (Excellent)

Study Rundown: Non-muscle-invasive urothelial cancer is the most common form of bladder cancer; however, many recur following initial resection warranting close follow-up and ultimately repeat resection. Most commonly these cancers are removed via transurethral resection of bladder tumor (TURBT), and as of now, it is not widespread practice to instill postresection intravesical chemotherapy. In this randomized controlled trial, instilling postresection chemotherapy, specifically gemcitabine, was found to decrease tumor recurrence in non-muscle-invasive urothelial cancer when compared to saline treatment as a placebo. However, this significant decrease in tumor recurrence was not found in patients with high-grade non-muscle-invasive urothelial cancer or carcinoma in-situ, and there was no difference in all-cause mortality in patients who received gemcitabine as compared to placebo.

While this is one of the largest randomized studies to evaluate the effectiveness of postresection intravesical chemotherapy, results should be interpreted with caution, as they may not be generalizable beyond white males. Furthermore, information regarding tumor size at diagnosis or surgery was not collected and may contribute to subsequent tumor progression.

Click to read study, published in JAMA

RELATED REPORTS

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Relevant Reading: Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

In-Depth [randomized clinical trial]: SWOG SO337 was a multicenter, double-blind, randomized clinical trial that recruited 406 eligible patients with non-muscle-invasive urothelial cancer from January 23, 2008 to August 14, 2012. Participants were followed for four years post TURBT, and 201 were randomized to receive gemcitabine and 193 were randomized to receive saline with 190 and 168 undergoing a transurethral resection of bladder tumor, respectively. Patients were included if they had suspected low-grade papillary urothelial cancer based on cystoscopy performed for symptoms of bladder cancer, such as hematuria and excluded if they had a prior non-urothelial or muscle-invasive bladder cancer, if within 18 months of index TURBT, had any high-grade or more than 2 low-grade non-muscle invasive urothelial cancers, had intravesical therapy within the prior 6 months., previous pelvic radiotherapy, or prior treatment for a malignancy within 5 years except for non-melanoma skin cancer or non-muscle-invasive bladder urothelial cancer. In an intention-to-treat analysis, 67 patients in the gemcitabine group and 91 patients in the saline group experienced a recurrence within the 4-year median follow-up (HR 0.66; CI95 0.48 to 0.90). Among patients with low-grade disease, time to recurrence was significantly lower in the gemcitabine group as compared to the saline group (HR 0.53; CI95 0.35 to 0.81). In a post-hoc analysis, 86 patients were diagnosed with high-grade non-muscle-invasive urothelial cancer or carcinoma in-situ, and there was no difference in recurrence in those that received gemcitabine compared to those that received saline (HR, 0.84; CI95 0.45 to 1.60; p = 0.38). Overall, there was no difference in all-cause mortality between the two treatment groups (HR 0.68; CI95 0.37 to 1.27).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bladder cancercancergemcitabine
Previous Post

Emotional regulation intervention linked to decreased high risk sexual behavior

Next Post

Parental cannabis use increasing, cigarette use decreasing

RelatedReports

All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

July 2, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Next Post
Parental cannabis use increasing, cigarette use decreasing

Parental cannabis use increasing, cigarette use decreasing

2 Minute Medicine Rewind May 14, 2018

Surgical repair improves survival and pain control in patients with dementia who suffer hip fracture

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
  • 2 Minute Medicine Rewind July 7, 2025
  • Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.